An observational study in Breast Neoplasms and Radiation, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to female participants. Per ClinicalTrials.gov, last updated 2024-07-01.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven — 7 open to participants now, 8 under way, 1 of them phase 3. Breast Neoplasms · Universitaire Ziekenhuizen KU Leuven.
Among the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven, this one is the 10th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2011, is one of 10 observational ones, and was the 6th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 40–80 · Women only
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18–100 · Women only
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 2
First in 2005; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 100 across the 21 interventional studies, 69 across the 10 observational. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07373782Phase 3Universitaire Ziekenhuizen KU LeuvenContinuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer | 2026-12 |
| NCT06415032Universitaire Ziekenhuizen KU LeuvenQuilting Sutures After Mastectomy | 2027-04 |
| NCT06324721Universitaire Ziekenhuizen KU LeuvenWho and Why do Patients Report Lymphedema After Breast Cancer Treatment Without an Objective Measurable Swelling | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study has the purpose to investigate the benefit of treating breast cancer patients in prone position. This treatment is compared to the standard technique in our center (supine position with or without respiratory gating). The investigators want to compare the doses on the organs at risk (heart and lungs) in the different techniques.
Patients who have an indication for radiotherapy of the breast and/or the lymph nodes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Started Jan 2011 (actual). Primary completion is estimated for Oct 2025, 177 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitaire Ziekenhuizen KU Leuven →